Relative Fund Performance vs {{ fund.benchmark.peers.peerCount }} peers using {{ fund.benchmark.name }} as their benchmark.
| 1M | 3M | 6M | 1Y p.a. | 2Y p.a. | 3Y p.a. | 5Y p.a. | 10Y p.a. | |
| Total return | -5.04% | 9.94% | 27.89% | 30.36% | 14.72% | 12.44% | 3.43% | 10.64% |
| Growth return | -2.24% | -3.4% | 28.38% | 29.44% | 8.19% | 12.1% | -0.18% | 2.75% |
| Income return | -2.8% | 13.34% | -0.49% | 0.92% | 6.53% | 0.34% | 3.61% | 7.89% |
| Type | Description |
| Platinum International Health Sciences | |
| Platinum Asset Management | |
| PLA0005AU | |
| Not Rated | |
| Unknown | |
| 5 Nov 2003 | |
| $204300170 million (as at 31 Jan 2026) | |
| $2.7137 (as at 12 Feb 2026) | |
| $2.7055 (as at 12 Feb 2026) | |
| Open |
| Type | Description |
| MER | 1.35% (as at 1 Dec 2025) |
| Indirect Cost Ratio (ICR) | 1.35% (as at 30 Jun 2025) |
| Minimum initial investment | $10,000.00 |
| Minimum additional investments | |
| Minimum redemption amount | $10,000.00 |
| Holding (as at 31 Oct 2025) | Type | % of Portfolio |
| Speedx Pty Ltd | Alternatives - Private Equity | 5.24% |
| Login now to view the complete list of holdings. | ||
The objective of the Platinum International Health Sciences managed fund is The Fund primarily invests in health care companies listed on securities markets around the world. It invests in companies engaged in many aspects of providing products and services to the health care industry such as biotechnology, pharmaceuticals, diagnostics, laboratory technologies, distribution, hospitals and nursing care, health insurance and the provision of information technology to such companies.
The strategy of the Platinum International Health Sciences managed fund is The Fund primarily invests in health care companies listed on securities markets around the world. It invests in companies engaged in many aspects of providing products and services to the health care industry such as biotechnology, pharmaceuticals, diagnostics, laboratory technologies, distribution, hospitals and nursing care, health insurance and the provision of information technology to such companies.
The APIR code of the Platinum International Health Sciences managed fund is PLA0005AU.
Platinum International Health Sciences’s total return last month was -5.04%. This was made up of a growth return of -2.24% and an income return of -2.8%. These returns were calculated as at 31 Jan 2026.
Platinum International Health Sciences’s total return for the last three months was 9.94%. This was made up of a growth return of -3.4% and an income return of 13.34%%. These returns were calculated as at 31 Jan 2026.
Platinum International Health Sciences’s one-year total return is 30.36%. This was made up of a growth return of 29.44% and an income return of 0.92%. These returns were calculated as at 31 Jan 2026.
Platinum International Health Sciences’s one-year total return is 12.44%. This was made up of a growth return of 12.1% and an income return of 0.34%. These returns were calculated as at 31 Jan 2026.
The asset allocation of the Platinum International Health Sciences managed fund is :
The Responsible Entity for the Platinum International Health Sciences managed fund is Platinum Asset Management.
As at 31 Jan 2026, the size of the Platinum International Health Sciences managed fund was $204300170 million.
The Platinum International Health Sciences managed fund has an inception date of 5 Nov 2003.
The current entry price of the Platinum International Health Sciences managed fund is $2.7137 per unit and the current exit price is $2.7055 per unit (as at 12 Feb 2026).
The current exit price of the Platinum International Health Sciences managed fund is $2.7055 per unit and the current entry price is $2.7137 per unit (as at 12 Feb 2026).
The minimum initial investment amount for the Platinum International Health Sciences managed fund is $10,000. Minimum additional investment is $0.
Fund data sourced from Morningstar. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only. Whilst every care has been taken in producing these numbers, neither Morningstar nor InvestSMART can make any guarantees around the complete accuracy of these figures. Should you decide to change investments, please read all relevant disclosure documents including the Product Disclosure Statements and if required, you may consider speaking to a financial professional for further guidance. A tax event may be realised as a result of switching investments. Past performance is not a reliable indicator of future performance.